Shen Hsin-Wei, Vice President of Medical Affairs, BizLink Biotech Venture Capital

In the early stages of medical innovation and entrepreneurship, good ideas often originate from real clinical pain points. However, whether an idea has true market potential is a much higher hurdle to clear. Many medical startups fail not because the technology is immature or lacks clinical value, but because they fail to properly assess market viability.
This article explores how to evaluate whether a medical innovation is worth bringing to the market from multiple perspectives—supported by real-world examples and international insights—to help entrepreneurs build sound judgment.

Does the Clinical Need Have “Scalable Demand”?

Even if a medical innovation addresses a real clinical pain point, founders must ask:
“Does this problem affect enough people?”
or more precisely:
“Is there a sufficiently large market willing to pay for this solution?”

For example, rare disease patients may have very urgent needs, but without special policy support—such as orphan drug designation or tax incentives—the market size may not justify high development costs.
In contrast, digital health management tools for chronic diseases like diabetes or hypertension may have lower technical difficulty but offer far broader user bases and strong scalability, thus exhibiting better business potential.

Founders can reference epidemiological data, national health insurance expenditure reports, and global market research data to estimate market size and growth potential.

Can the Innovation Be Naturally Integrated into Clinical Workflow?

Market viability is tightly linked to workflow integration.
If a medical product requires clinicians, nurses, or technicians to learn new skills or significantly modify existing processes, adoption rates drop dramatically.

A good example is Velano Vascular’s needle-free blood draw device PIVO, which seamlessly integrates into existing inpatient workflows. Such design reduces the learning curve and increases adoption from clinicians and healthcare administrators.

Founders should run workflow simulation interviews, asking clinical users to describe a full day’s work and observing whether the proposed product disrupts their routine. The fewer workflow interruptions, the higher the adoption likelihood.

Does It Have Potential for Reimbursement or Insurance Coverage?

Even if a product has strong clinical value, lack of reimbursement can make it seem like a “luxury item” for patients or hospitals. This is a common “high value but low adoption” dilemma in medical innovation.

For example, home ECG patches saw limited adoption before reimbursement approval; once covered by health plans, market acceptance expanded rapidly.

Startup teams must analyze target countries’ reimbursement systems, procedural codes (CPT, DRG), and pathways for HTA (Health Technology Assessment) or payment applications early in the product life cycle.

Is There Sufficient Procurement Motivation and Go-to-Market Channels?

Medical purchasing decisions are often complex; end users are not always the decision-makers.
For example:

• Users: nurses

• Decision-makers: hospital administration or procurement committees

Moreover, large-scale adoption requires channels such as distributors, KOL endorsements, and medical societies. Without these, even good products struggle to enter the market.

Founders should build a Stakeholder Map to outline all parties involved, their motivations, and influence, then prepare tailored messaging and supporting materials for each role.

Does It Meet Regulatory Requirements and Expectations?

From concept to commercialization, medical products must comply with regulations—from safety and performance to data privacy, clinical validation, and device classification.

For example, if AI algorithms are involved, additional regulatory scrutiny applies. In the U.S. and EU, the rules governing AI-based medical devices are evolving rapidly.
Early collaboration with regulatory consultants can help determine whether the product falls under FDA, TFDA, or CE certification pathways and allow founders to plan ahead.

Does It Attract Investors and Strategic Partners?

A medical innovation’s success often depends not only on market demand or technological readiness but also on whether it can secure the right investors and partners.

In Australia, Europe, and the U.S., medical VCs often prefer products with clear clinical positioning and potential for acquisition.
Gaining support from major medical centers, research institutes, and pharmaceutical companies can significantly increase chances of success.

Founders should participate in accelerators, VC matchmaking events, and prepare stage-appropriate pitch decks covering market analysis, clinical validation, regulatory strategies, and return expectations.

Does It Have Clear Competitive Positioning?

Understanding the competitive landscape is essential in evaluating market viability.
If dozens of similar solutions already exist, differentiation becomes critical.

Teams should examine:

• Competitor density

• Development stages of similar products

• Market penetration

• User feedback

Tools such as a Positioning Matrix help visualize functional gaps, target segments, pricing strategies, and regulatory progress to identify market entry opportunities.

Market Viability: The Bridge Between Ideas and Real-World Impact

At its core, medical entrepreneurship is not just about technology—it is about turning ideas into solutions that leave the lab, enter the hospital, and reach the patient.

Evaluating market viability is a necessary discipline for every medical founder.
Remember: you are not solving a “problem”—
you are solving a problem that is worth solving, that someone will pay for, and that can truly be implemented.

The earlier you validate your idea across these dimensions, the smoother and more resilient your entrepreneurial journey will be.